CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM

15-Aug-2024 - CureVac N.V.announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma. CVGBM is CureVac’s first investigational cancer vaccine based on its proprietary second-generation mRNA backbone. It encodes a single fusion protein comprising ...

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Restructuring includes a workforce reduction of approximately 30%

04-Jul-2024 - CureVac N.V. announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need. The restructuring includes a workforce reduction of approximately 30% to create a leaner, more agile organization ...

CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

17-Apr-2024 - CureVac N.V. and The University of Texas MD Anderson Cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, ...

CureVac Announces Update to the Management Team

Chief Scientific Officer resigned

18-Jul-2023 - CureVac N.V. announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer,has stepped down effective July 14, 2023 to return to early-stage research in the United States. During the search for a successor, CureVac’s Chief Development Officer, Dr. Myriam Mendila, will head the advancement ...

CureVac appoints new CEO

Dr. Franz-Werner Haas to complete tenure as CEO by March 31, 2023

10-Jan-2023 - CureVac N.V. announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, 2023. Dr. Alexander Zehnder will succeed Dr. Haas, joining from Sanofi on April 1, 2023. “The recent clinical ...

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

09-Jan-2023 - CureVac N.V. announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK. The preliminary results generated by this ...

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

19-Aug-2022 - CureVac N.V. announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to ...

Personalized cancer vaccines: CureVac acquires oncology startup

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

10-Jun-2022 - CureVac N.V. announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. “The addition of Frame’s technology and talent to CureVac’s oncology research ...

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency

12-Apr-2022 - CureVac N.V. and GSK announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government ...

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate

01-Apr-2022 - CureVac N.V. announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s ...